OncoSenX
OncoSenX develops targeted cancer therapies that use a proteo-lipid vehicle to deliver plasmid DNA, inducing apoptosis in cancer cells based on their transcriptional activity. Its approach aims to precisely target solid tumors while minimizing side effects and avoiding harm to healthy cells.
Facts
- HQ
- Seattle, Washington
- Sectors
- Biotechnology, Therapeutics, Oncology
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
OncoSenX extends oversubscribed SAFE, plans $30M Series A to fund Phase I for genetics-targeted cancer therapies
Seattle biotech OncoSenX extended an oversubscribed SAFE to raise more capital for its lipid nanoparticle gene-delivery cancer therapies and plans a $30 million Series A to fund a Phase I trial; the spinout has raised $4.1 million so far and has six employees.
OncoSenX raises $3M to advance non-viral, gene-delivery cancer therapeutics targeting solid tumors
Seattle startup OncoSenX raised $3 million to advance a non-viral, lipid nanoparticle gene-delivery platform that aims to selectively kill solid tumor cells based on their genetic mutations, and plans to use the funding to accelerate preclinical work toward Phase 1 trials.
People
-
Eric Garcia Executive, Chief Operating Officer
-
Matthew Scholz Executive, Chief Executive Officer
-
Stephen Hilbert Executive, Chief Business Officer